What is IMA's market cap?

$46.31M, based on the Nov 5 close of $4.08.

Does ImageneBio pay a dividend?

No regular cash dividend has been paid in the last year.

How much of IMA is sold short?

61.3K shares, 0.6% of float, as of Oct 15, 2026.

What sector is IMA in?

Healthcare, in the Biotechnology industry.

NASDAQ · IMAHealthcareBiotechnology

ImageneBio, Inc. Common Stock (IMA)

$4.08−0.49%

Close Nov 5, 2026 · split-adjusted

Nov 4, 2026$4.10▼ 50.24% in range

Nov 4, 2025Low $4.00 · High $8.61Nov 4, 2026

What changed · written from our data

As of Nov 5, 2026

ImageneBio closed at $4.08 on Nov 5, down 0.49%, within 2.0% of its 52-week closing low. Volume of 5.4K shares was 0.40× its 20-day average (below normal).

Split-adjusted performance: -11.5% over one month, -31.0% over six months, -50.5% over one year.

Short interest was 61.3K shares at the Oct 15 settlement, up 86.7% from the prior report (0.6% of float, 4.2 days to cover).

Market cap$46.3M11.4M shares

Revenue · quarter$0.00—

Diluted EPS$-0.63—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range4.00 – 8.61−52.6% from high

Volume5.4K0.40× 20-day avg

Volatility · 60d34.6%Annualised

Short % of float0.6%4.2 days to cover

Net cash$136.2MCash $136.2M

Next earnings—Not scheduled

Split-adjusted performance

1W +0.7%1M −11.5%3M −28.3%6M −31.0%YTD −40.9%1Y −50.5%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum42

Revenue growth—

Net margin—

Value (low P/E)—

Size25

Industry medians: 6-month return −24.1%, revenue growth +8.5%, net margin −226.4%, P/E 21.4×.

Short interest

Details →

Shares short61.3K+86.7% vs prior

Days to cover4.2Settled Oct 15

% of float0.6%

Short vol. 10d42.8%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
IMAImageneBio	$4.08	−0.49%	−31.0%	—	—	—	$46.3M
TILInstil Bio	$6.97	−0.29%	−13.2%	—	—	—	$47.3M	Compare
CRBUCaribou Biosciences	$0.4069	−8.44%	−78.4%	−43.8%	−1619.9%	—	$43.6M	Compare
GRMLGreenland Mines	$3.62	−7.42%	—	—	—	—	$49.5M	Compare
KLRSKalaris Therapeutics	$2.10	+3.96%	−59.2%	—	—	—	$50.0M	Compare
ELOXEloxx Pharmaceuticals	$12.59	−1.18%	—	—	—	—	$50.8M	Compare
INKTMiNK Therapeutics	$10.10	−4.70%	−9.7%	—	—	—	$51.6M	Compare
LONALeonaBio	$4.32	−5.40%	−56.2%	—	—	—	$40.7M	Compare
EXOZeXoZymes	$4.11	−4.64%	−58.9%	—	—	—	$38.2M	Compare

News about ImageneBio

All news →

No recent articles focused on ImageneBio.

Quick answers

What does ImageneBio do?: ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L).
What is IMA's market cap?: $46.31M, based on the Nov 5 close of $4.08.
Does ImageneBio pay a dividend?: No regular cash dividend has been paid in the last year.
How much of IMA is sold short?: 61.3K shares, 0.6% of float, as of Oct 15, 2026.
What sector is IMA in?: Healthcare, in the Biotechnology industry.

About ImageneBio

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

HQ: San Diego, CA18 employeesListed Jul 28, 2025imagenebio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology